To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Nickel(II) sulfate
Nickel(II) sulfate or just nickel sulfate, usually refers to the chemical compound with the formula NiSO4.6H2O. This blue salt is a common laboratory source of nickel. It also occurs as the rare mineral Retgersite. The anhydrous salt, NiSO4, a high melting solid, is also known but is less commonly encountered. These nickel(II) compounds are paramagnetic. Additional recommended knowledge
Synthesis and structureDissolution of nickel hydroxide in sulfuric acid followed by evaporation produces crystals of this salt or the corresponding heptahydrate. X-ray crystallography measurements show that NiSO4.6H2O consists of octahedral [Ni(H2O)6]2+ ions. These ions in turn are hydrogen bonded to sulfate ions.[1] Dissolution of the salt in water gives solutions containing the ion [Ni(H2O)6]2+. Coordination chemistryNiSO4.6H2O and related hydrates react with ammonia to give [Ni(NH3)6]SO4 and with ethylenediamine to give [Ni(H2NCH2CH2NH2)3]SO4. The latter is occasionally used as a calibrant for magnetic susceptibility measurements because it has no tendency to hydrate. ApplicationsNiSO4.6H2O in combination with boric acid or nickel(II) chloride is used in some electroplating baths. SafetyNickel salts are considered carcinogenic. References
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nickel(II)_sulfate". A list of authors is available in Wikipedia. |
- Adolescent Body Mass Index (BMI) can predict early occurence of diabetes and heart disease in adulthood - New England Journal of Medicine Study Shows that BMI at Adolescence in the Normal Range Can Nevertheless Predict Risk of Early Type 2 Diabetes and Heart Disease in a Differential Manner
- Algeta completes enrolment of 900 patients into phase III ALSYMPCA trial with Alpharadin - Primary endpoint is overall survival in castration-resistant prostate cancer (CRPC) patients with bone metastases
- LDC schließt Kooperationsabkommen zur Entwicklung einer neuartigen Krebstherapie
- Veröffentlichung in Immunobiology beschreibt Wirkmechanismus des BiTE-Antikörpers MT110 - Studie zeigt, wie schon sehr geringe Mengen von Micromets gegen EpCAM gerichteter BiTE-Antikörper Krebszellen absterben lassen
- Dresdner Bioinformatik bekommt namhafte Unterstützung - Klaus Tschira Stiftung ermöglicht Aufbau von zwei neuen Forschungsgruppen an der TU Dresden